-
Professor Xian Zhang: Follow-Up Data on ALL Patients Who Did Not Undergo Transplantation After CAR-T Therapy丨13th Lu Daopei Hematology Conference
PART 1 In ALL patients achieving deep remission after CAR-T therapy, are there clear clinical or biological features that help identify those most suitable for a non-transplant approach? How do…
-
Conquering Multiple Myeloma: Professor Jesús San Miguel Shares 45 Years of Research Excellence and the Five Pillars on the Path to a Cure| EHA 2025
The 2025 European Hematology Association (EHA) Annual Congress was grandly convened in Milan, Italy, bringing together the world’s top hematology experts for an academic feast. At this congress, Professor Jesús San Miguel of the University of Navarra Clinic in Spain was honored with EHA Lifetime Achievement Award for his revolutionary contributions to the field of…
-
Professor Rakesh Popat Elaborates on the Phase I Study Results of the Novel BCMA/GPRC5D/CD3 Trispecific Antibody丨EHA 2025
In 2025, the 30th Annual Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology field, this year’s congress attracted thousands of experts and scholars from around the world, with nearly 4,000 abstracts submitted. Among the many studies, a Phase I clinical trial of the…
-
Key Findings of the Phase III POLARGO Study Highlight Pola-R-GEMOX as a Potential New Standard of Care for Transplant-Ineligible Patients丨EHA 2025
Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma in adults. For patients who are relapsed or refractory after first-line therapy and are not candidates…
-
SURPASS-ET Study Results Released: Ropeginterferon as Second-Line Therapy for High-Risk ET Achieves Dual Breakthrough in Efficacy and Safety丨EHA 2025
At the recently held International Congress of Hematology, treatment advances in the field of Myeloproliferative Neoplasms (MPN) have garnered significant attention. As a classic subtype of MPN, Essential Thrombocythemia (ET) has seen no substantial breakthroughs in its treatment over the past two decades. In a Plenary Presentation, Professor Harry Gill of the University of Hong…
-
Professor David Curtis Elaborates on the Breakthrough Results of the ALLG BM12 CAST Study丨EHA 2025
The 30th European Hematology Association (EHA) Annual Meeting 2025 was grandly held in Milan, Italy, gathering top experts from the global hematology community to discuss and share the latest research progress and cutting-edge technologies in the field. During the Plenary Session, Professor David Curtis from the Australasian Leukaemia and Lymphoma Group (ALLG), on behalf of…
-
Subverting Traditional Concepts: CLL Does Not Originate from a Single Clone; Multiple Independent Minor Clones Plant the “Seeds” Early On丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in person, gathering top experts and cutting-edge research from the global hematology community. At this conference, a revolutionary study on the origin of Chronic Lymphocytic Leukemia (CLL) attracted widespread attention. A research team from Spain, using multi-omics single-cell sequencing technologies, revealed…
-
Professor Jakob Kather Elaborates on the Evolution and Future Prospects of AI in Hematologic Oncology丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was held in a hybrid format, both online and in-person, gathering top experts and scholars from the global hematology community. The conference focused on the deep integration of cutting-edge technology and clinical practice, with the application of Artificial Intelligence (AI) being one of the core topics. Professor…
Connecting Medical Expertise through Media